Alembic obtains FDA approval for generic Zaroxolyn

Patients who have swelling and water retention caused by heart failure or kidney diseases, will soon have a new generic treatment.

The Food and Drug Administration has cleared Alembic’s metolazone tablets in dosage strengths of 2.5 mg, 5 mg, and 10 mg.

Alembic’s product is the generic of Lannett’s Zaroxolyn tablets.

The product is indicated for treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases, and including the nephrotic syndrome and states of diminished renal function.